Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin

Drug and Chemical Toxicology

Volumn 29, Issue 3, 2006, Pages 303-312

  Seop Kim, Dong ^a   Kim, Ki Suk ^b   Hwan Choi, Ki ^a   Na, Hankwang ^a   Kim, Joo Il ^a   Shin, Won Ho ^b   Kim, Eun Joo ^b,c  

^a National Institute of Toxicological Research   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Action potential; Fluoroquinolones; hERG; QT interval prolongation

Indexed keywords

BALOFLOXACIN; GEMIFLOXACIN; POTASSIUM CHANNEL HERG; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; ELECTROPHYSIOLOGY; FEMALE; HEART VENTRICLE ARRHYTHMIA; IC 50; MEMBRANE DEPOLARIZATION; MEMBRANE STEADY POTENTIAL; MICROELECTRODE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PURKINJE FIBER; QT PROLONGATION; RABBIT; REPOLARIZATION; TECHNIQUE; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FLUOROQUINOLONES; HEART; NAPHTHYRIDINES; POTASSIUM CHANNEL BLOCKERS; PURKINJE FIBERS; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 33745685439     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540600652996     Document Type: Article

References (17)

1. Allen, A., Bygate, E., Oliver, S., Johnson, M., Ward, C., Cheon, A. J., Choo, Y. S., Kim, I. C. (2000). Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 44:1604-1608.
2. Ball, P. (2000). Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob. Chemother. 45:557-559.
3. Ben-David, J., Zipes, D. P. (1993). Torsaes de pointes and proarrhythmia. Lancet 341:1578-1582.
4. Chiba, K., Sugiyama, A., Satoh, Y., Shiina, H., Hashimoto, K. (2000). Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol. Appl. Pharmacol. 169:8-16.
5. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., Keating, M. T. (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
6. Hagiwara, T., Sotoh, S., Kasai, Y., Takasuna, K. (2001). A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn. J. Pharmacol. 87:231-234.
7. Jaillon, P., Morganroth, J., Brumpt, I., Talbot, G., Sparfloxacin Safety Group. (1996). Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J. Antimicrob. Chemother. 37(Suppl. A): 161-167.
8. + channel HERG. Mol. Pharmacol. 59:122-126.
9. Kozawa, O., Uematsu, T., Matsuno, H., Niwa, M., Nagashima, S., Kanamaru, M. (1996). Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrobial. Agents Chemother. 40:2824-2828.
10. Lipsky, B. A., Baker, C. A. (1999). Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 28:352-364.
11. Morganroth, J., Hunt, T., Dorr, M. B., Magner, D., Talbot, G. H. (1999a). The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin. Ther. 21:1171-1181.
12. Morganroth, J., Talbot, G. H., Dorr, M. B., Johnson, R. D., Geary, W., Magner, D. (1999b). Effects of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin. Ther. 21:818-828.
13. Nakagawa, T., Ishigai, M., Kato, M., Hayakawa, N., Kinoshita, H., Okutomi, T., Ohkubo, K., Okazaki, A. (1995). Pharmacokinetics of the new fluoroquinolone balofloxacin in mice, rats, and dogs. Arzneimittelforschung 45(6):719-22.
14. Obana, M., Irimajiri, S., Tomizawa, I., Takizawa, Y., Sakamoto, Y., Nitta, Y., Tsunoda, T., Fukuda, H., Yamaguchi, T., Masuda, G. I. (1995). Clinical study of balofloxacin on infectious enteritis and assessment of the fecal drug concentration and intestinal microbial flora in patients with infectious enteritis. Research group of balofloxacin on infectious enteritis, Kansenshogaku Zasshi 69(9):991-1006.
15. Sanguinetti, M. C. (1999). Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann. N.Y. Acad. Sci. 868:406-413.
16. Stahlmann, R., Lode, L. (1999). Toxicity of quinolones. Drugs 58(2):37-42.
17. Whitney, G. G., Fawley, M. M., Hadler, J., Harrison, L. H., Lexau, C., Renigold, A., Lefkowitz, L., Cieslak, P. R., Certron, M., Zell, E. R., Jorgensen, J. H., Schuchat, A. (2000). Increasing prevalence of multidrug-resistance Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.